Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: The role of hypomethylating agents

Current Cancer Drug Targets

Volumn 13, Issue 6, 2013, Pages 661-669

  Martino, Massimo ^a   Fedele, Roberta ^a   Moscato, Tiziana ^a   Ronco, Francesca ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

AML; Azacitidine; Decitabine; GVHD; GvL; Hematopoietic progenitor cell transplant; Hypomethylating agents; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BORTEZOMIB; DNA METHYLTRANSFERASE; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MELANOMA ANTIGEN 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DNA METHYLATION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; INFECTIOUS COMPLICATION; LEUKEMIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANIMALS; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84888095824     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990005     Document Type: Article

References (67)

1. Malcovati, L.; Nimer, S. D. Myelodysplastic syndromes: diagnosisand staging. Cancer Control. 2008, 15 (Suppl), 4-13.
2. National Cancer Institute SEER Cancer Statistics Review 1975-2009. http://seer.cancer.gov/csr/1975_2009_pops09/2012.
3. Bacher, U.; Talano, J. A.; Bishop, M. R. Monitoring and preventionof relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol. Blood Marrow. Transplant. 2012, 18, S62-S73.
4. Dohner, H.; Estey, E. H.; Amadori, S.; Appelbaum, F. R.; Buchner, T.; Burnett, A. K.; Dombret, H.; Fenaux, P.; Grimwade, D.; Larson, R. A.; Lo-Coco, F.; Naoe, T.; Niederwieser, D.; Ossenkoppele, G. J.; Sanz, M. A.; Sierra, J.; Tallman, M. S.; Lowenberg, B.; Bloomfield, C. D. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010, 115, 453-474.
5. Laubach, J.; Rao, A. V. Current and emerging strategies for themanagement of acute myeloid leukemia in the elderly. Oncologist 2008, 13, 1097-1108.
6. Klepin, H. D.;Balducci, L. Acute myelogenous leukemia in olderadults. Oncologist 2009, 14, 222-232.
7. Luger, S.; Sacks, N. Bone marrow transplantation formyelodysplastic syndrome--who? when? and which? Bone. Marrow. Transplant. 2002, 30, 199-206.
8. Deeg, H. J.; Scott, B. L.; Fang, M.; Shulman, H. M.; Gyurkocza, B.; Myerson, D.; Pagel, J. M.; Platzbecker, U.; Ramakrishnan, A.; Radich, J. P.; Sandmaier, B. M.; Sorror, M.; Stirewalt, D. L.; Wilson, W. A.; Storb, R.; Appelbaum, F. R.; Gooley, T. Five-group cytogenetic risk classification, monosomal karyotype and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012,
9. Field, T.; Perkins, J.; Huang, Y.; Kharfan-Dabaja, M. A.; Alsina, M.; Ayala, E.; Fernandez, H. F.; Janssen, W.; Lancet, J.; Perez, L.; Sullivan, D.; List, A.; Anasetti, C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone. Marrow. Transplant. 2010, 45, 255-260.
10. Scott, B. L.; Storer, B.; Loken, M. R.; Storb, R.; Appelbaum, F. Reeg, Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol. Blood Marrow. Transplant. 2005, 11, 65-73.
11. Brunstein, C. G.; Gutman, J. A.; Weisdorf, D. J.; Woolfrey, A. Defor, T. E.; Gooley, T. A.; Verneris, M. R.; Appelbaum, F. R.; Wagner, J. E.; Delaney, C. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116, 4693-4699.
12. Verneris, M. R.; Brunstein, C. G.; Barker, J.; MacMillan, M. DeFor, McKenna, D. H.; Burke, M. J.; Blazar, B. R.; Miller, J. S.; McGlave, P. B.; Weisdorf, D. J.; Wagner, J. E. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114, 4293-4299.
13. Hegenbart, U.; Niederwieser, D.; Sandmaier, B. M.; Maris, M. B. Shizuru, J. A.; Greinix, H.; Cordonnier, C.; Rio, B.; Gratwohl, A.; Lange, T.; Al-Ali, H.; Storer, B.; Maloney, D.; McSweeney, P.; Chauncey, T.; Agura, E.; Bruno, B.; Maziarz, R. T.; Petersen, F.; Storb, R. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol. 2006, 24, 444-453.
14. Storb, R. Reduced-intensity conditioning transplantation in myeloidmalignancies. Curr. Opin. Oncol. 2009, 21 (Suppl 1), S3-S5.
15. Warlick, E. D.; Cioc, A.; DeFor, T.; Dolan, M.; Weisdorf, D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol. Blood Marrow. Transplant. 2009, 15, 30-38.
16. Cornelissen, J. J.; van Putten, W. L.; Verdonck, L. F.; Theobald, M.; Jacky, E.; Daenen, S. M.; van Marwijk, K. M.; Wijermans, P.; Schouten, H.; Huijgens, P. C.; van der, L. H.; Fey, M.; Maertens, J.; Gratwohl, A.; Lowenberg, B. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007, 109, 3658-3666.
17. Schetelig, J.; Bornhauser, M.; Schmid, C.; Schwerdtfeger, R.; Martin, H.; Stelljes, M.; Hegenbart, U.; Schafer-Eckart, K.; Fussel, M.; Wiedemann, B.; Thiede, C.; Kienast, J.; Baurmann, H.; Ganser, A.; Kolb, H. J.; Ehninger, G. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J. Clin. Oncol. 2008, 26, 5183-5191.
18. US National Library of Medicine. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002286/2012.
19. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358,1148-1159.
20. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Finelli, C.; Giagounidis, A.; Schoch, R.; Gattermann, N.; Sanz, G.; List, A.; Gore, S. D.; Seymour, J. F.; Bennett, J. M.; Byrd, J.; Backstrom, J.; Zimmerman, L.; McKenzie, D.; Beach, C.; Silverman, L. R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet. Oncol. 2009, 10, 223-232.
21. Fenaux, P.; Mufti, G. J.; Hellstrom-Lindberg, E.; Santini, V.;Gattermann, N.; Germing, U.; Sanz, G.; List, A. F.; Gore, S.; Seymour, J. F.; Dombret, H.; Backstrom, J.; Zimmerman, L.; McKenzie, D.; Beach, C. L.; Silverman, L. R. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J. Clin. Oncol. 2010, 28, 562-569.
22. Santini, V.; Fenaux, P.; Mufti, G. J.; Silverman, L. R.; List, A.; Gore, S. D.; Seymour, J. F.; Backstrom, J.; Beach, C. L. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur. J. Haematol. 2010, 85, 130-138.
23. Seymour, J. F.; Fenaux, P.; Silverman, L. R.; Mufti, G. Hellstrom-Lindberg, E.; Santini, V.; List, A. F.; Gore, S. D.; Backstrom, J.; McKenzie, D.; Beach, C. L. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev. Oncol. Hematol. 2010, 76, 218-227.
24. la Porta, M. G.; Malcovati, L.; Strupp, C.; Ambaglio, I.; Kuendgen, A.; Zipperer, E.; Travaglino, E.; Invernizzi, R.; Pascutto, C.; Lazzarino, M.; Germing, U.; Cazzola, M. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96, 441-449.
25. Al-Ali, H. K.; Jaekel, N.; Junghanss, C.; Maschmeyer, G.; Krahl, R.; Cross, M.; Hoppe, G.; Niederwieser, D. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk. Lymphoma. 2012, 53, 110-117.
26. Hollenbach, P. W.; Nguyen, A. N.; Brady, H.; Williams, M.; Ning, Y.; Richard, N.; Krushel, L.; Aukerman, S. L.; Heise, C.; MacBeth, K. J. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5, e9001.
27. Kantarjian, H. M.; Thomas, X. G.; Dmoszynska, A.; Wierzbowska, A.; Mazur, G.; Mayer, J.; Gau, J. P.; Chou, W. C.; Buckstein, R.; Cermak, J.; Kuo, C. Y.; Oriol, A.; Ravandi, F.; Faderl, S.; Delaunay, J.; Lysak, D.; Minden, M.; Arthur, C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 2012, 30, 2670-2677.
28. Craddock, C.; Jilani, N.; Siddique, S.; Vyas, P.; Dennis, M.; Yin, J.; Russell, N.; Snowden, J.; Crawley, C. Azacitidine is well tolerated after allogeneic stem cell transplantation and its administration is associated with a reduced risk of acute graft-versus-host disease. Haematologica 2012,97 (suppl 1), 21.
29. Hill, G. Ferrara, J. L. The primacy of the gastrointestinal tract asa target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000, 95, 2754-2759.
30. Cassileth, P. A.; Harrington, D. P.; Appelbaum, F. R.; Lazarus, H.M.; Rowe, J. M.; Paietta, E.; Willman, C.; Hurd, D. D.; Bennett, J. M.; Blume, K. G.; Head, D. R.; Wiernik, P. H. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 1998, 339, 1649-1656.
31. Zittoun, R. A.; Mandelli, F.; Willemze, R.; de, W. T.; Resegotti, L.; Leoni, F.; Damasio, E.; Visani, G.; Papa, G.;. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N. Engl. J. Med. 1995, 332, 217-223.
32. Yan, C. H.; Liu, D. H.; Liu, K. Y.; Xu, L. P.; Liu, Y. R.; Han, W.; Wang, Y.; Qin, Y. Z.; Huang, X. J. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012, 119, 3256-3262.
33. Weiden, P. L.; Flournoy, N.; Thomas, E. D.; Prentice, R.; Buckner, C. D.; Storb, R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl.J. Med. 1979, 300, 1068-1073.
34. Cao, J.; Chen, C.; Zeng, L.; Li, L.; Li, Z.; Xu, K. Engineeredregulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leuk Res 2010, 34, 1374-1382.
35. Edinger, M.; Hoffmann, P.; Ermann, J.; Drago, K.; Fathman, C. G.; Strober, S.; Negrin, R. S. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 2003, 9, 1144-1150.
36. Floess, S.; Freyer, J.; Siewert, C.; Baron, U.; Olek, S.; Schlawe, K.; Chang, H. D.; Bopp, T.; Schmitt, E.; Klein-Hessling, S.; Serfling, E.; Hamann, A.; Huehn, J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007, 5, e38.
37. Tao, R.; de Zoeten, E. F.; Ozkaynak, E.; Chen, C.; Wang, L.; Porrett, P. M.; Li, B.; Turka, L. A.; Olson, E. N.; Greene, M. I.; Wells, A. D.; Hancock, W. W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 2007, 13, 1299-1307.
38. Santourlidis, S.; Trompeter, H. I.; Weinhold, S.; Eisermann, B.; Meyer, K. L.; Wernet, P.; Uhrberg, M. Crucial role of DNA methylation in determination of clonally distributed killer cell Iglike receptor expression patterns in NK cells. J. Immunol. 2002, 169, 4253-4261.
39. Choi, J.; Ritchey, J.; Prior, J. L.; Holt, M.; Shannon, W. D.; Deych, E.; Piwnica-Worms, D. R.; DiPersio, J. F. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116, 129-139.
40. Chan, H. W.; Kurago, Z. B.; Stewart, C. A.; Wilson, M. J.; Martin, M. P.; Mace, B. E.; Carrington, M.; Trowsdale, J.; Lutz, C. T. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J. Exp. Med. 2003, 197, 245-255.
41. Sanchez-Abarca, L. I.; Gutierrez-Cosio, S.; Santamaria, C.; Caballero-Velazquez, T.; Blanco, B.; Herrero-Sanchez, C.; Garcia, J. L.; Carrancio, S.; Hernandez-Campo, P.; Gonzalez, F. J.; Flores, T.; Ciudad, L.; Ballestar, E.; Del, C. C.; San Miguel, J. F.; Perez Simon, J. A. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115, 107-121.
42. Goodyear, O. C.; Dennis, M.; Jilani, N. Y.; Loke, J.; Siddique, S.; Ryan, G.; Nunnick, J.; Khanum, R.; Raghavan, M.; Cook, M.; Snowden, J. A.; Griffiths, M.; Russell, N.; Yin, J.; Crawley, C.; Cook, G.; Vyas, P.; Moss, P.; Malladi, R.; Craddock, C. F. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119, 3361-3369.
43. Goodyear, O.; Agathanggelou, A.; Novitzky-Basso, I.; Siddique, S.; McSkeane, T.; Ryan, G.; Vyas, P.; Cavenagh, J.; Stankovic, T.; Moss, P.; Craddock, C. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116, 1908-1918.
44. Cruz, C. R.; Gerdemann, U.; Leen, A. M.; Shafer, J. A.; Tzou, B.; Horton, T. M.; Sheehan, A.; Copeland, A.; Younes, A.; Rooney, C. M.; Heslop, H. E.; Bollard, C. M. Improving T-celltherapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin. Cancer Res. 2011, 17, 7058-7066.
45. Maio, M.; Coral, S.; Fratta, E.; Altomonte, M.; Sigalotti, L.Epigenetic targets for immune intervention in human malignancies. Oncogene 2003, 22, 6484-6488.
46. Shafer, J. A.; Cruz, C. R.; Leen, A. M.; Ku, S.; Lu, A.; Rousseau, A.; Heslop, H. E.; Rooney, C. M.; Bollard, C. M.; Foster, A. E. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 2010, 51, 870-880.
47. Koreth, J.; Schlenk, R.; Kopecky, K. J.; Honda, S.; Sierra, J.; Djulbegovic, B. J.; Wadleigh, M.; DeAngelo, D. J.; Stone, R. M.; Sakamaki, H.; Appelbaum, F. R.; Dohner, H.; Antin, J. H.; Soiffer, R. J.; Cutler, C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009, 301, 2349-2361.
48. Bornhauser, M.; Oelschlaegel, U.; Platzbecker, U.; Bug, G.; Lutterbeck, K.; Kiehl, M. G.; Schetelig, J.; Kiani, A.; Illmer, T.; Schaich, M.; Theuser, C.; Mohr, B.; Brendel, C.; Fauser, A. A.; Klein, S.; Martin, H.; Ehninger, G.; Thiede, C. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009, 94, 1613-1617.
49. Nakasone, H.; Kanda, Y.; Takasaki, H.; Nakaseko, C.; Sakura, T.; Fujisawa, S.; Yokota, A.; Yano, S.; Usuki, K.; Maruta, A.; Abe, D.; Hoshino, T.; Takahashi, S.; Kanamori, H.; Okamoto, S. Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosomepositive leukemia. Leukemia 2010, 24, 1236-1239.
50. de, L. M.; Giralt, S.; Thall, P. F.; de Padua, S. L.; Jones, R. Komanduri, K.; Braun, T. M.; Nguyen, H. Q.; Champlin, R.; Garcia-Manero, G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116, 5420-5431.
51. Itzykson, R.; Fenaux, P. Optimizing hypomethylating agents inmyelodysplastic syndromes. Curr. Opin. Hematol. 2012, 19, 65-70.
52. Jabbour, E.; Giralt, S.; Kantarjian, H.; Garcia-Manero, G.; Jagasia,M.; Kebriaei, P.; de, P. L.; Shpall, E. J.; Champlin, R.; de, L. M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115, 1899-1905.
53. Platzbecker, U.; Wermke, M.; Radke, J.; Oelschlaegel, U.; Seltmann, F.; Kiani, A.; Klut, I. M.; Knoth, H.; Rollig, C.; Schetelig, J.; Mohr, B.; Graehlert, X.; Ehninger, G.; Bornhauser, M.; Thiede, C. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26, 381-389.
54. Villela, L. M.;Bolanos-Meade, J. Blood and bone marrowtransplantation for acute myeloid leukemia. Clinical Leukemia 2009, 3, E11-E21.
55. Huff, C. A.; Fuchs, E. J.; Smith, B. D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R. A.; Flinn, I. W.; Ambinder, R. F.; Borrello, I. M.; Matsui, W. H.; Vogelsang, G. B.; Griffin, C. A.; Luznik, L.; Jones, R. J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol. Blood Marrow. Transplant. 2006, 12, 414-421.
56. Porter, D. L.; Collins, R. H., Jr.; Hardy, C.; Kernan, N. Giralt, S.; Flowers, M. E.; Casper, J.; Leahey, A.; Parker, P.; Mick, R.; Bate-Boyle, B.; King, R.; Antin, J. H. Treatment of relapsed leukemia after unrelated donor marrowtransplantation with unrelated donor leukocyte infusions. Blood 2000, 95, 1214-1221.
57. Schmid, C.; Labopin, M.; Nagler, A.; Bornhauser, M.; Fassas, A.; Volin, L.; Gurman, G.; Maertens, J.; Bordigoni, P.; Holler, E.; Ehninger, G.; Polge, E.; Gorin, N. C.; Kolb, H. J.; Rocha, V. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 2007, 25, 4938-4945.
58. Bolanos-Meade, J.; Smith, B. D.; Gore, S. D.; McDevitt, M., 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol. Blood Marrow. Transplant. 2011, 17, 754-758.
59. Mapara, M. Y.; Kim, Y. M.; Wang, S. P.; Bronson, R.; Sachs, D.H.; Sykes, M. Donor lymphocyte infusions mediate superior graftversus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002, 100, 1903-1909.
60. Reddy, P.; Maeda, Y.; Liu, C.; Krijanovski, O. I.; Korngold, R.;Ferrara, J. L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat. Med. 2005, 11, 1244-1249.
61. Schmid, C.; Schleuning, M.; Ledderose, G.; Tischer, J.; Kolb, H. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 2005, 23, 5675-5687.
62. Czibere, A.; Bruns, I.; Kroger, N.; Platzbecker, U.; Lind, J. Zohren, F. Fenk, Germing, U.; Schroder, T.; Graf, T.; Haas, R.; Kobbe, G. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone. Marrow. Transplant. 2010, 45, 872-876.
63. Graef, T.; Kuendgen, A.; Fenk, R.; Zohren, F.; Haas, R.; Kobbe, G.Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk. Res. 2007, 31, 257-259.
64. Lubbert, M.; Bertz, H.; Wasch, R.; Marks, R.; Ruter, B.; Claus, R.; Finke, J. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone. Marrow. Transplant. 2010, 45, 627-632.
65. Schroeder, T.; Czibere, A.; Kroger, N.; Platzbecker, U.; Uharek, L.; Luft, T.; Wolschke, C.; Bruns, I.; Zohren, F.; Fenk, R.; Haas, R.; Kobbe, G. Phase II study of azacitidine and donor lymphocytr infusions as first salavage therapy in patients with acute myeloid leukemia or myelodysplastic syndromes relapsing after allogeneic HSCT: final results of the AZARELA study. Blood 2011, 118 (suppl).
66. Ganguly, S.; Amin, M.; Divine, C.; Aljitawi, O. S.; Abhyankar, S.;McGuirk, J. P. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann. Hematol. 2013, 92 (4), 549-550.
67. Ravandi, F.; Kantarjian, H.; Cohen, A.; Davis, M.; Anderlini, P.; Andersson, B.; Claxton, D.; Donato, M.; Gajewski, J.; Khouri, I.; Korbling, M.; Ueno, N.; deVos, D.; Champlin, R.; Giralt, S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001, 27, 1221-1225.